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ABSTRACT
Objectives: Many UK primary care trusts have
recently introduced eligibility criteria restricting
total knee replacement (TKR) to patients with low
pre-operative Oxford Knee Scores (OKS) to cut
expenditure. We evaluate these criteria by assessing
the cost-effectiveness of TKR compared with no knee
replacement for patients with different baseline
characteristics from an NHS perspective.
Design: The cost-effectiveness of TKR in different
patient subgroups was assessed using regression
analyses of patient-level data from the Knee
Arthroplasty Trial, a large, pragmatic randomised trial
comparing knee prostheses.
Setting: 34 UK hospitals.
Participants: 2131 osteoarthritis patients undergoing
TKR.
Interventions and outcome measures: Costs and
quality-adjusted life years (QALYs) observed in the
Knee Arthroplasty Trial within 5 years of TKR were
compared with conservative assumptions about the
costs and outcomes that would have been accrued had
TKR not been performed.
Results: On average, primary TKR and 5 years of
subsequent care cost £7458 per patient (SD: £4058),
and patients gained an average of 1.33 (SD: 1.43)
QALYs. As a result, TKR cost £5623/QALY gained.
Although costs and health outcomes varied with age
and sex, TKR cost <£20000/QALY gained for patients
with American Society of Anaesthesiologists grades
1e2 who had baseline OKS <40 and for American
Society of Anaesthesiologists grade 3 patients with
OKS <35, even with highly conservative assumptions
about costs and outcomes without TKR. Body mass
index had no signiﬁcant effect on costs or outcomes.
Restricting TKR to patients with pre-operative OKS
<27 would inappropriately deny a highly cost-effective
treatment to >10000 patients annually.
Conclusions: TKR is highly cost-effective for most
current patients if the NHS is willing to pay
£20000e£30000/QALY gained. At least 97% of TKR
patients in England have more severe symptoms than
the thresholds we have identiﬁed, suggesting that
further rationing by OKS is probably unjustiﬁed.
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ARTICLE SUMMARY
Article focus
- We assess the cost-effectiveness of total knee
replacement (TKR) compared with no knee
replacement for patients with different baseline
characteristics from a NHS perspective.
- In particular, we assess the appropriateness of
eligibility criteria recently introduced by many UK
primary care trusts, which restrict TKR to
patients with low (ie, poor) pre-operative
Oxford Knee Scores (OKS) to cut expenditure.
Key messages
- We ﬁnd TKR to be highly cost-effective, costing
£5623 per quality-adjusted life year gained for
the average patient.
- TKR costs <£20000 per quality-adjusted life
year gained for healthy patients with OKS of <40
or <35 for patients who have other conditions
restricting their daily activities.
- We ﬁnd no evidence to support the criteria for
restricting access to TKR that have been
proposed by some primary care trusts and
calculate that restricting TKR to those patients
with pre-operative OKS of 26 or less would deny
a highly cost-effective treatment to >10000
patients/year.
Strengths and limitations of this study
- This is the ﬁrst study assessing how the cost-
effectiveness of TKR varies with OKS and the ﬁrst
assessing the clinical/economic implications of
the newly introduced rationing criteria.
- Analyses are based on patient-level data from
a large pragmatic trial with detailed prospective
collection of utilities, baseline characteristics and
all major knee-related NHS resource use,
including revisions and ambulatory care.
- Our study makes several highly conservative
assumptions: in particular, assuming that
patients would have accrued no knee-related
costs and remained at baseline utility without
TKR. Furthermore, the Knee Arthroplasty Trial
sample included only 37 patients with pre-
operative OKS >35. As result, TKR may be
also cost-effective for some patients with OKS
above 39.
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Total knee replacement (TKR) is a highly effective
treatment for patients with bone-on-bone osteoarthritis
and signiﬁcant knee symptoms, producing substantial
reductions in symptoms (particularly pain)
1 and lasting
for at least 15 years in 83%e94% of cases.
2 However,
about 18% of patients consider the outcomes of their
surgery to be only fair or poor,
1 and a small proportion
experience complications.
3e5 Previous economic evalu-
ations have found TKR to be highly cost-effective, with
a cost-effectiveness ratio between €1276 and $18300 per
quality-adjusted life year (QALY) gained for the average
patient
6e10: well below the £20000e£30000/QALY
range that the National Institute for Health and Clinical
Excellence (NICE) considers cost-effective.
11 However,
studies suggest that the costs and beneﬁts of TKR vary
between patient subgroups, with TKR being more cost-
effective in younger patients,
9 those attending high-
volume centres
7 and those deemed low-risk based on
age, comorbidities and poverty criteria.
7 There is also
evidence that older
12 and obese
13 patients have higher
medical costs, although other studies suggest that knee
replacement is also cost-effective in non-agenarians
14
and draw conﬂicting conclusions on how beneﬁts vary
with body mass index (BMI).
15e17
In the current economic environment, there is great
pressure to reduce NHS expenditure, and numerous
Primary Care Trusts (PCTs) have proposed cutting costs
by limiting access to joint replacement
18e25 or classifying
these procedures as being of limited value.
24e26 Since
around 60000 primary TKR procedures are conducted in
England and Wales each year,
27 savings could be made
with little loss of patient welfare if it were possible to
reliably predict which patients obtain little/no beneﬁt
from TKR based on explicit evidence-based criteria.
Although the widely used Oxford Knee Score (OKS) was
developed to assess outcomes of knee replacement in
trial populations,
28 several PCTs have set maximum
OKS thresholds (ranging from 18 to 32), above which
patients are ineligible for TKR.
18e24 However, we are not
aware of any clinical or cost-effectiveness justiﬁcation for
these thresholds. Furthermore, many patients with
higher OKS have signiﬁcant symptoms or limitations to
daily activities that could be improved by surgery. If
rationing policies are to be adopted, cost-effectiveness
analysis offers the only fair basis for designing them since
it ensures that NHS resources are allocated to maximise
the health gained from available resources. As treatments
are generally considered cost-effective if they cost
<£20000e£30000 per QALY gained,
11 restricting TKR
to those patients for whom the procedure costs
<£20000e£30000/QALY gained would be a reasonable
approach, potentially realising savings that could be
invested in other treatments giving greater health gains.
However, we are aware of no published evidence assessing
how the cost-effectiveness of TKR varies with OKS.
We therefore use data from the Knee Arthroplasty
Trial (KAT)
29 30 to assess the appropriateness of
rationing knee replacement by OKS, age, BMI and clin-
ical characteristics, by calculating the cost-effectiveness
of TKR in different patient subgroups. In contrast to
previous studies evaluating the cost-effectiveness of TKR
that relied upon data from small cohorts with short
follow-up,
6e10 14 the KAT trial data set provides detailed
prospective individual patient data on baseline charac-
teristics, treatments, complications, costs and quality of
life and now has >5 years’ follow-up on 2352 patients.
METHODS
We assessed the cost-effectiveness of primary TKR
compared with no knee replacement for patients with
different baseline characteristics. Our analysis took
a NHS perspective and excluded personal and social
services from the analysis, although TKR is likely to delay
admission to residential care,
14 reduce personal care
costs and help recipients to continue paid employment.
A cost-utility analysis was conducted, which assessed cost-
effectiveness as the cost per QALY gained to capture the
quality of life gains associated with TKR.
Data on costs and quality of life following TKR were
taken from the KAT trial (ISRCTN 45837371): a prag-
matic, partial-factorial, unblinded randomised controlled
trial in which 2352 participants attending 34 UK centres
were randomly allocated to undergo TKR with/without
a metal-backed tibial component, with/without patellar
resurfacing and/or with/without a mobile bearing.
29 30
Five-year trial results demonstrated that patients experi-
ence substantial improvements in quality of life and
functional status following knee replacement that are
maintained out to 5 years
30; further follow-up is ongoing.
Our analysis took a 5-year time horizon in line with the
results published to date
30; costs and health beneﬁts
occurring >5 years after primary TKR were conservatively
excluded.
KAT participants completed the OKS and EQ-5D
questionnaires immediately before and 3 months after
TKR and annually thereafter. The OKS is a validated 12-
item questionnaire for assessing health status and
outcomes in relation to knee replacement that gives an
unweighted total score ranging from 0 (severe problems
on all items) to 48 (no problems on any item).
28 The
EQ-5D is a generic health state preference measure
31;
health state preference values (‘utilities’) for EQ-5D
proﬁles were based on time-trade-off valuations by
members of the UK general public.
31 EQ-5D utilities
range from  0.594 (extreme problems on all ﬁve
domains) to 1 (perfect health) and indicate the value
placed on different levels of health. The number of
QALYs that each patient accrued following TKR was
calculated as the area under the utility curve, with linear
interpolation between utility measurements; those
patients who died were assumed to remain at the last
observed utility until death.
Healthcare resource use data (including knee-related
outpatient, general practice and physiotherapy consul-
tations and theatre time, hospital days, complications
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Rationing of total knee replacementand knee components used during the primary admis-
sion for TKR and during any knee-related readmissions
or revisions) were collected prospectively for all KAT
participants and valued at 2007e2008 prices, as
described previously.
30 Costs incurred after year 1 were
discounted at 3.5% per year based on current UK
recommendations.
32
The number of QALYs gained from TKR was calcu-
lated as the number of QALYs observed minus the
number of QALYs expected without TKR. Since all KAT
participants underwent TKR, assumptions were needed
to estimate the costs and QALYs that would have been
accrued if no TKR procedures had occurred in the 5-year
time horizon. We assumed the following:
< Without TKR, patients would have remained at their
baseline EQ-5D utility for 5 years or until death (if
sooner). In practice, patients’ symptoms and quality
of life are likely to deteriorate due to worsening
arthritis
17 33 and increasing age;
34
< The seven KAT participants who died before hospital
discharge would have survived for 5 years at baseline
utility without TKR but that TKR had no effect on the
date of death for other patients. This assumption is
highly conservative since those patients who die soon
after joint replacement tend to be older
53 5and have
comorbidities that could have led to death without
TKR.
5
< Patients would not have used any healthcare
resources due to their knee problems if they had
not undergone TKR. This assumption is highly
conservative since osteoarthritis patients will receive
medical management without TKR, and a recent
Canadian caseecontrol study suggested that TKR
recipients accrued lower costs 6e18 months after the
procedure than matched controls who had arthritis
but no TKR.
33
Since these assumptions are likely to underestimate
the beneﬁts and overestimate the additional costs of
TKR, we evaluated the effect of relaxing these assump-
tions in sensitivity analyses.
The 7% of data on baseline characteristics, resource
use and quality of life that were missing were imputed by
multiple imputation using the ice command
36e38
(V.1.3.0) within Stata V.11.0, thereby avoiding the bias
and inefﬁciency associated with complete case analy-
sis.
38e40 Treatment indicators and the covariates
included in subsequent regression analyses were
included in the imputation model to avoid bias.
38 Fifty
imputed data sets were generated and results combined.
Regression models were used to estimate how the costs
and QALYs gained from TKR vary with baseline charac-
teristics and to predict outcomes for different patient
groups without subdividing the trial population into
small patient subgroups. Since costs and QALYs were
highly skewed, generalised linear models with gamma
family distributions were used to predict total costs and
the QALYs accrued with or without TKR; prior to
regression, the number of QALYs accrued was subtracted
from the maximum number of QALYs that could have
been accrued over the 5-year trial period to ensure
that all QALY data were positive. We evaluated the effect
of six baseline characteristics on costs and QALYs
with/without TKR:
< male,
< age at time of operation,
< baseline OKS (using the new, 0e48, scoring system
41),
< American Society of Anaesthesiologists (ASA) grade 3
(symptomatic illness with minimal restriction on daily
life) rather than grades 1 (ﬁt and healthy) or 2
(asymptomatic illness with no restriction on daily
life),
< BMI (kg/m
2),
< presence of arthritis in one knee rather than in both
knees or generally.
Since the introduction of biologic therapies has
changed management of rheumatoid arthritis and as
rheumatoid arthritis patients and those with severe
comorbidities are likely have very different costs and
outcomes from most patients, 108 rheumatoid arthritis
patients and 13 patients with ASA grade 4 were excluded
from the analysis. One hundred patients who were
randomised to total versus unicompartmental knee
replacement or died or withdrew from the trial before
surgery were also excluded from the analysis, giving
a ﬁnal sample size of 2131.
All regression analyses were conducted in Stata V.11.
Bootstrapping was used to capture uncertainty around
incremental cost-effectiveness ratios (ICERs) and corre-
lations between costs and QALYs with/without TKR; the
regression models for costs and outcomes were run for
each of the 125 bootstrap samples drawn from each
imputed KAT data set and results combined using
Rubin’s rule.
39 Predicted costs and the predicted
number of QALYs accrued with and without TKR in
different patient groups were calculated from regression
coefﬁcients and used to estimate ICERs. Bootstrap
results were used to calculate cost-effectiveness accept-
ability curves,
42 which plot the probability of treatment
being cost-effective against the ceiling ratio (ie, the
maximum that society is willing or able to pay per QALY
gained).
We also calculated the number of patients in England
and Wales eligible for TKR under different rationing
policies based on 61651 patients undergoing primary
TKR each year.
27 The proportion of patients eligible for
TKR under different rationing criteria was based on
analysis of an extract of patient-level Patient Reported
Outcome Measures
1 data on admissions for knee
replacement up to 31 December 2010, supplemented
where necessary by the baseline characteristics from the
KAT sample.
RESULTS
Of the 2131 KAT participants who had osteoarthritis,
were ASA grades 1e3 and underwent TKR as part of
the trial, the mean baseline OKS was 18 (SD: 7.5), mean
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(956/2131) were men (ﬁgure 1); further baseline char-
acteristics of the trial population have been reported
previously.
29
Mean EQ-5D utility rose substantially within 3 months
of TKR from 0.39 at baseline to 0.71 at 1 year and
declined gradually thereafter (ﬁgure 1, table 1).
However, baseline utility and the quality of life gains
associated with TKR varied between patient subgroups.
In particular, women and patients with low OKS (ie, poor
knee function), higher ASA grade or obesity at baseline
tended to have lower quality of life at all timepoints
(ﬁgure 1), although those in the lowest OKS quintile
experienced signiﬁcantly greater health gains from TKR
than the top quintile (p<0.001; calculated using linear
regression, combining imputed data sets using the mim
command).
On average, each admission for primary TKR cost
£6363 (SD: £1702). Readmissions, revision procedures
and GP, outpatient and physiotherapy consultations
related to the study knee over the following 5 years cost
af u r t h e r£1095 (SD: £3579) per patient, giving a total
cost of £7458 (SD: £4058) per patient. TKR was more
costly in patients with low baseline OKS, but the greater
QALY gains meant that TKR was better value for money
in this patient group than in patients with moderate
symptoms (table 1). Subgroup analyses suggested that
TKR cost <£11000/QALY gained across all OKS
deciles: well below the £20000e£30000/QALY gained
range that NICE currently consider good value for
money.
11
However, cost-effectiveness also varied substantially
between patients within each OKS decile. We therefore
used regression models to estimate the costs, QALY gains
and cost-effectiveness of TKR in a wide range of patient
subgroups while controlling for multiple baseline char-
acteristics. Our results indicated that four factors have
a signiﬁcant effect on cost-effectiveness: age, sex, base-
line OKS and ASA grade (table 2). BMI and the presence
of arthritis in other joints besides the study knee had no
signiﬁcant effect on either the costs or QALY gains
associated with TKR (p>0.05).
Figure 2 shows the cost-effectiveness of TKR for each
multivariate group, using charts similar in design to
widely used cardiovascular risk tables.
43 The charts
demonstrate that TKR is clearly cost-effective across
a wide range of patient groups. For example, TKR costs
<£20000/QALY gained for 71-year old women with no
symptomatic illness unless baseline OKS is above 40
(equivalent to having very minor problems on up to
eight of the 12 activities mentioned in OKS or moderate-
to-severe pain only on exertion). The threshold OKS at
which TKR becomes cost-ineffective was lower for older
patients, men and those with symptomatic disease, but
TKR remained cost-effective for all patients with OKS
below 32 regardless of age, sex or ASA grade. A simpli-
ﬁed analysis controlling only for OKS and ASA grade
suggested that TKR is cost-effective for all ASA grade 1 or
2 patients with baseline OKS <40, and all ASA grade 3
patients with OKS <35.
There was substantial uncertainty around the cost-
effectiveness ratios for patients with very high baseline
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Rationing of total knee replacementOKS since only 37 trial participants had OKS above 35 at
baseline. However, we estimate that there is a 99%
probability that TKR is cost-effective (at a £20000/QALY
ceiling ratio) for the average ASA grade 1e2 patient with
a baseline OKS of 35 and a 53% probability for ASA
grade 3 (ﬁgure 3).
Since each additional baseline characteristic increases
the complexity of the eligibility criteria and may also
raise ethical or equity concerns, we estimated the
number of patients who would receive TKR under
different eligibility criteria. This analysis suggested that
restricting TKR to those patients for whom the operation
was predicted to cost <£20000/QALY gained based on
the simpliﬁed model (allowing only for ASA grade and
OKS) would lead to 2000 fewer TKR procedures being
conducted in England and Wales each year (3% fewer
than the 61651 procedures conducted in 2009/2010
27).
If the decision rules were simpliﬁed further to provide
TKR to all patients with baseline OKS <39, all but 1700
of the 61651 patients currently receiving TKR in
England and Wales in 2009/2010
27 would be eligible.
Allowing for other baseline characteristics had minimal
effect on patient numbers or predicted costs or beneﬁts,
suggesting that decisions about suitability for TKR can
be based on OKS alone.
Sensitivity analyses were conducted to assess the effect
of extending the time horizon of our analysis up to
10 years and of assuming that EQ-5D utility would have
fallen by 0.5% per year without TKR,
34 that all knee-
related ambulatory consultations would have occurred
without TKR and that the mean length of stay has fallen
by 41% (5.9 days
27 vs 10.0) since the KAT operations
took place in the period 1999e2003. Changing any of
these assumptions produced lower ICERs than the base
case analysis, conﬁrming that the current analysis is
highly conservative and suggesting that TKR may be cost-
effective for ASA grade 1e2 patients with baseline OKS
as high as 43. Excluding patients with incomplete data
had no effect on conclusions. Although statistically
signiﬁcant, adding an age-squared term to the regression
model had no effect on the conclusions, while a sensi-
tivity analysis adding an OKS-squared term suggested
that TKR may be cost-effective for all patients of ASA
grade 1 or 2. Recoding BMI as a dummy variable indi-
cating whether or not patients were obese (BMI $30)
did not change the conclusions, and obesity had no
signiﬁcant effect on costs or QALYs.
DISCUSSION
We found TKR to cost £5623/QALY gained for the
average patient (similar to estimates from previous
studies
6e10) and therefore represent very good value for
money compared with the £20000e£30000/QALY
threshold typically used in NHS decision making.
11 Our
study also conﬁrms previous ﬁndings
791 7that costs and
Table 2 Results of the regression analysis
Baseline characteristic
Coefﬁcient (SE)
QALY loss with TKRy QALY loss without TKRy Total costs with TKR (£)
Male 0.056 (0.065)  0.001 (0.054) 593 (181)*
Age at operation (years) 0.007 (0.003)* 0.002 (0.004)  8 (12)
Pre-operative OKS  0.040 (0.004)*  0.087 (0.004)*  52 (12)*
ASA grade 3 0.414 (0.067)* 0.227 (0.087)* 492 (208)*
Constant 1.712 (0.201)* 4.274 (0.325)* 8573 (881)*
The incremental cost-effectiveness ratio (expressed as cost per QALY) for any given patient equals: (male3593dage38dOKS352 + ASA
grade 33492 + 8573)/((male3 0.001 + age30.002dOKS30.087+ ASA grade 330.227+4.274)d(male30.056 + age30.007dOKS30.040+
ASA grade 330.414+1.712)). Costs and quality-adjusted life years (QALYs) were discounted at 3.5% per annum.
*p<0.05.
yQALY loss indicates the number of discounted QALYs that would have been accrued if patients had experienced an EQ-5D utility of 1 for
5 years (4.67 QALYs) minus the number of discounted QALYs that the patient actually experienced.
ASA, American Society of Anaesthesiologists classiﬁcation (1¼completely ﬁt and healthy, 2¼some illness but no effect on daily activity,
3¼symptomatic illness with minimal restriction on life); OKS, Oxford Knee Score (new scoring system running from zero (severe problems on all
functions) to 48 (no problems))
41; QALY, quality-adjusted life year; TKR, total knee replacement.
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Figure 2 Cost-effectiveness prediction charts estimated
based on predictions of regression models. ASA, American
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and healthy, 2¼some illness but no effect on daily activity,
3¼symptomatic illness with minimal restriction on life); OKS,
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Rationing of total knee replacementbeneﬁts vary with age and comorbidity but evaluates
such characteristics, and pre-operative knee function, in
multivariate analyses, which has not (to our knowledge)
been done previously. We found pre-operative OKS to be
the best predictor of post-operative costs, outcomes and
cost-effectiveness.
Our analyses were based on patient-level data from
a large trial with detailed prospective collection of costs,
utilities and baseline characteristics that permit exten-
sive subgroup analyses. KAT used a pragmatic design
with broad inclusion criteria and no restrictions on peri-
or post-operative care other than randomised aspects of
component design
29 30; as a result, the trial cohort is
similar to the national Patient Reported Outcome
Measures cohort, and costs and beneﬁts are likely to be
comparable to those in routine clinical practice.
Furthermore, unlike some previous economic evalua-
tions, our study took full account of uncertainty and
included all knee-related NHS costs accrued in the ﬁrst
5 years after TKR. The main limitation of our analysis
was the small number of patients with high OKS. Since
KAT recruited only 37 patients with OKS >35, further
studies are required to evaluate TKR in this patient
subgroup. Analyses were also based on post hoc
comparisons between outcomes before and after TKR,
rather than between randomly assigned treatment
groups. As a result, our study does not provide unbiased
estimates of the QALY gains from TKR, and regression
towards the mean may have caused our study to over-
estimate the quality of life improvement attributable
to TKR and/or the effect of pre-operative OKS on
QALY gains.
We made several highly conservative assumptions, in
particular, assuming that patients would have accrued no
knee-related costs and would have remained at baseline
utility without TKR, whereas previous studies have found
that patients accrue substantial costs and show clinical
worsening without TKR.
33 We also assumed that those
patients who died before hospital discharge would have
survived for 5 years if they had not had TKR; in reality,
those patients dying soon after TKR tend to be older
53 5
and frailer
5 pre-operatively, and some studies suggest
that patients undergoing hip replacement have higher
long-term survival than the general population
44 45
(although this may be due to patient selection
35 44).
When these assumptions were relaxed, TKR was cost-
effective for ASA grade 1e2 patients with baseline OKS
<44. The costs and beneﬁts of TKR are likely to vary
between centres and over time due to variations in
patient demographics, component prices, length of stay
and operation time; sensitivity analyses demonstrated
that TKR may have become more cost-effective since the
KAT procedures were conducted in the period
1999e2003 due to reductions in length of stay.
Our analyses show that if TKR were to be rationed
based on cost-effectiveness, OKS would be a reasonable
tool to use to set the threshold, although there may, of
course, be practical difﬁculties with using a patient-
reported measure to determine treatment eligibility:
particularly if patients know how their questionnaire
responses will be used or if test-retest reliability is low in
this setting. The decision to operate must also take into
consideration other factors, such as radiographic ﬁnd-
ings and patient choice. Based on regression and
subgroup analyses, we can be conﬁdent that TKR costs
<£20000/QALY for all ASA grade 1e2 patients with
baseline OKS <40 and for ASA grade 3 patients with
OKS <35. Using these thresholds to determine who
received treatment would avoid around 2000 TKR
procedures per year in England and Wales, saving
around £11.8 million/year. However, the higher thresh-
olds suggested by sensitivity analyses using less conser-
vative assumptions suggest that TKR is cost-effective for
all but 100 patients/year, which is unlikely to achieve
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Rationing of total knee replacementsufﬁcient savings to warrant rationing of TKR. Although
the cost-effectiveness of knee replacement was also
inﬂuenced by gender and age, taking account of these
factors as well as OKS and ASA grade would increase the
complexity of eligibility criteria, reduce equality of access
to healthcare and have minimal effect on NHS budgets.
The results also demonstrate that the thresholds
proposed by some PCTs
18e24 are inappropriate and would
deny a highly cost-effective treatment to thousands of
patients with severe arthritis. The current situation also
introduces a postcode lottery with different PCTs using
different eligibility criteria. We estimate that limiting knee
replacement to patients with OKS #26 would prevent
>10000 people from receiving TKR. This would be
inequitable as TKR costs £10697/QALY gained for this
group, whereas the NICE routinely recommend treat-
ments with ICERs in the region of £20000e£30000/
QALY gained
11 46 47 and are willing to pay substantially
more for end of life care.
48 Furthermore, the ﬁnding that
TKR and subsequent monitoring is more costly for
patients with low OKS suggests that delaying TKR until
symptoms have deteriorated may be a false economy.
Although some PCTs have considered restricting TKR
further for obese patients,
18 21 25 49 we found BMI to have
no signiﬁcant effect on costs (p¼0.442), QALY gains
(p¼0.098) or the incidence of peri- or post-operative
complications (p>0.26). Although BMI remained non-
signiﬁcant even when ASA grade was omitted from
regression analyses, it is difﬁcult to isolate the effect of
obesity from other correlated variables (eg, comorbidity);
as a result, further research on obesity may be warranted,
particularly since a previous study observed a signiﬁcant
correlation between BMI and costs.
13
Eligibility criteria for rheumatoid arthritis patients and
patients with ASA grade 4 remain unclear, although ASA
grade 4 patients would normally be considered unﬁt for
surgery, and the decision to operate on such patients
would be based on a case-by-case consideration of
whether the beneﬁts outweigh the risks. While our
study focused on the costs and beneﬁts of TKR, patients
with high baseline OKS often undergo unicompart-
mental knee replacement; further research is needed to
evaluate how the cost-effectiveness of unicompartmental
replacement varies with OKS.
In conclusion, TKR is highly cost-effective for the vast
majority of patients who currently undergo this proce-
dure in the UK. Although costs and health beneﬁts vary
with baseline OKS, the rationing thresholds proposed by
some PCTs
18e24 are not supported by evidence on health
outcomes or cost-effectiveness.
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